PURETECH HEALTH PLC (0VQ.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:0VQ - GB00BY2Z0H74 - Common Stock
0VQ.DE Key Statistics, Chart & Performance
The current stock price of 0VQ.DE is 1.41 EUR.
0VQ.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 74.11 | 49.10B | ||
| 1AE.DE | ARGENX SE | 72.79 | 48.22B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.83B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.65B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.41B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.75B | ||
| 5CV.DE | CUREVAC NV | 5.09 | 996.15M | ||
| NANO.PA | NANOBIOTIX | N/A | 819.66M | ||
| PHIL.MI | PHILOGEN SPA | 21.01 | 700.30M | ||
| IVA.PA | INVENTIVA SA | N/A | 544.06M | ||
| ALCLS.PA | CELLECTIS | N/A | 453.47M | ||
| FYB.DE | FORMYCON AG | N/A | 439.10M |
Related stock screener links
About 0VQ.DE
Company Profile
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Company Info
PURETECH HEALTH PLC
6 Tide Street, Suite 400
Boston MASSACHUSETTS US
Employees: 90
Phone: 16174822333
PURETECH HEALTH PLC / 0VQ.DE FAQ
What does PURETECH HEALTH PLC do?
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Can you provide the latest stock price for PURETECH HEALTH PLC?
The current stock price of 0VQ.DE is 1.41 EUR. The price decreased by -3.42% in the last trading session.
Does 0VQ stock pay dividends?
0VQ.DE does not pay a dividend.
What is the ChartMill rating of PURETECH HEALTH PLC stock?
0VQ.DE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists 0VQ stock?
0VQ.DE stock is listed on the Frankfurt Stock Exchange exchange.
Is PURETECH HEALTH PLC (0VQ.DE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 0VQ.DE.
What is the ownership structure of PURETECH HEALTH PLC (0VQ.DE)?
You can find the ownership structure of PURETECH HEALTH PLC (0VQ.DE) on the Ownership tab.
0VQ.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 0VQ.DE.
0VQ.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 0VQ.DE. 0VQ.DE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
0VQ.DE Financial Highlights
Over the last trailing twelve months 0VQ.DE reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 168.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 792.96% | ||
| ROA | 9.16% | ||
| ROE | 13.48% | ||
| Debt/Equity | 0.05 |
0VQ.DE Forecast & Estimates
5 analysts have analysed 0VQ.DE and the average price target is 6.05 EUR. This implies a price increase of 329.22% is expected in the next year compared to the current price of 1.41.
For the next year, analysts expect an EPS growth of -40.93% and a revenue growth -100% for 0VQ.DE